{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:06Z","timestamp":1789763946505,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304629"],"award-info":[{"award-number":["82304629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012549"],"award-info":[{"award-number":["2022A1515012549"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012667"],"award-info":[{"award-number":["2023A1515012667"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40261-023-01320-4","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:02:23Z","timestamp":1700751743000},"page":"949-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Wei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-8155","authenticated-orcid":false,"given":"Wanlong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"issue":"1","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol. 2020;16(12):706\u201315.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1320_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B. Spinal muscular atrophy: In the challenge lies a solution. Trends Neurosci. 2021;44(4):306\u201322.","journal-title":"Trends Neurosci"},{"issue":"2","key":"1320_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: Progress and challenges. Neurotherapeutics. 2015;12(2):290\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1320_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Nusinersen: First global approval. Drugs. 2017;77(4):473\u20139.","journal-title":"Drugs"},{"issue":"18","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79(11):1255\u201362.","journal-title":"Drugs"},{"issue":"17","key":"1320_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Risdiplam: First approval. Drugs. 2020;80(17):1853\u20138.","journal-title":"Drugs"},{"issue":"12","key":"1320_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Beldzinska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (firefish part 2): Secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1320_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (str1ve-eu): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, et al. Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs. Drug Metab Dispos. 2022;50(6):879\u201387.","journal-title":"Drug Metab Dispos"},{"key":"1320_CR13","doi-asserted-by":"crossref","unstructured":"Chand DH, Sun R, Diab KA, Kenny D, Tukov FF. Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings. Gene Ther. 2023; 30(9):685\u201397.","DOI":"10.1038\/s41434-023-00401-5"},{"issue":"5","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346.","journal-title":"J Neurol"},{"issue":"7","key":"1320_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the fda adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the fda adverse event reporting system. Psychother Psychosom. 2021;90(1):41\u20138.","journal-title":"Psychother Psychosom"},{"issue":"7\u20138","key":"1320_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357.","journal-title":"Drug Discov Today"},{"key":"1320_CR18","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6):bbab347.","DOI":"10.1093\/bib\/bbab347"},{"key":"1320_CR19","unstructured":"Fda. Fda adverse event reporting system public dashboard [Internet]. Available from: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed: 5 Mar 2023."},{"issue":"3","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","volume":"26","author":"EG Brown","year":"2003","unstructured":"Brown EG. Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (meddra). Drug Saf. 2003;26(3):145\u201358.","journal-title":"Drug Saf"},{"key":"1320_CR21","doi-asserted-by":"crossref","unstructured":"Pace ND, Multani JK. On the reporting of odds ratios and risk ratios. Nutrients. 2018;10(10):1512.","DOI":"10.3390\/nu10101512"},{"issue":"1","key":"1320_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1320_CR23","unstructured":"Oliveros JC. Venny. An interactive tool for comparing lists with venn\u2019s diagrams [Internet]. https:\/\/bioinfogp.cnb.csic.es\/tools\/venny\/index.html. Accessed: 19 May 2023."},{"issue":"9","key":"1320_CR24","first-page":"1501","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"Chakravarthy U, Adamis AP, Cunningham EJ, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113(9):1501\u20138.","journal-title":"Ophthalmology"},{"issue":"3","key":"1320_CR25","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1212\/WNL.0000000000002868","volume":"87","author":"HM Bahr","year":"2016","unstructured":"Bahr HM, Stone ML, Stosic M, Moss HE, Carrithers MD. Pearls & oy-sters: a rare presentation of chronic intracranial hypertension with concurrent deafness and blindness. Neurology. 2016;87(3):e26\u20138.","journal-title":"Neurology"},{"issue":"3","key":"1320_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D'Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, Herbert K, Barclay P, Cairns A, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339\u201350.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1320_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS. Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol. 2015;43(1):78\u201389.","journal-title":"Toxicol Pathol"},{"issue":"2","key":"1320_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","volume":"8","author":"J Friese","year":"2021","unstructured":"Friese J, Geitmann S, Holzwarth D, Muller N, Sassen R, Baur U, et al. Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec\u2014a single centre experience. J Neuromuscul Dis. 2021;8(2):209\u201316.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"1320_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","volume":"23","author":"GM Stettner","year":"2023","unstructured":"Stettner GM, Hasselmann O, Tscherter A, Galiart E, Jacquier D, Klein A. Treatment of spinal muscular atrophy with onasemnogene abeparvovec in Switzerland: a prospective observational case series study. Bmc Neurol. 2023;23(1):88.","journal-title":"Bmc Neurol"},{"issue":"3","key":"1320_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, Mcmillan H, Tukov FF, Montgomery K, Kleyn A, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (avxs-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560\u20136.","journal-title":"J Hepatol"},{"key":"1320_CR31","doi-asserted-by":"crossref","unstructured":"Bitetti I, Lanzara V, Margiotta G, Varone A. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther. 2023;30(7-8):592\u20137.","DOI":"10.1038\/s41434-022-00341-6"},{"issue":"1","key":"1320_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Weiss","year":"2022","unstructured":"Weiss C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1):17\u201327.","journal-title":"Lancet Child Adolesc Health."},{"issue":"6","key":"1320_CR33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","volume":"8","author":"N Hashemi","year":"2014","unstructured":"Hashemi N, Odze RD, Mcgowan MP, Santos RD, Stroes E, Cohen DE. Liver histology during mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol. 2014;8(6):606\u201311.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"1320_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen G, Burghes A, Hsieh C, Do J, Chu B, Perry S, et al. Biodistribution of onasemnogene abeparvovec dna, mrna and smn protein in human tissue. Nat Med. 2021;27(10):1701\u201311.","journal-title":"Nat Med"},{"issue":"10","key":"1320_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"issue":"9-S","key":"1320_CR36","first-page":"22","volume":"89","author":"C Spagnoli","year":"2018","unstructured":"Spagnoli C, Pisani F, Di Mario F, Leandro G, Gaiani F, De AG, et al. Peripheral neuropathy and gastroenterologic disorders: An overview on an underrecognized association. Acta Biomed. 2018;89(9-S):22\u201332.","journal-title":"Acta Biomed"},{"issue":"2","key":"1320_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/00075198-200204000-00011","volume":"8","author":"AJ Bauer","year":"2002","unstructured":"Bauer AJ, Schwarz NT, Moore BA, Turler A, Kalff JC. Ileus in critical illness: mechanisms and management. Curr Opin Crit Care. 2002;8(2):152\u20137.","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"1320_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.23582","volume":"72","author":"M Bowerman","year":"2012","unstructured":"Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol. 2012;72(2):256\u201368.","journal-title":"Ann Neurol"},{"issue":"1","key":"1320_CR39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcmgh.2021.01.019","volume":"12","author":"MO Deguise","year":"2021","unstructured":"Deguise MO, Pileggi C, De Repentigny Y, Beauvais A, Tierney A, Chehade L, et al. Smn depleted mice offer a robust and rapid onset model of nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 2021;12(1):354\u201377.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"1320_CR40","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00415-017-8405-3","volume":"264","author":"H Nakatsuji","year":"2017","unstructured":"Nakatsuji H, Araki A, Hashizume A, Hijikata Y, Yamada S, Inagaki T, et al. Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J Neurol. 2017;264(5):839\u201347.","journal-title":"J Neurol"},{"issue":"14","key":"1320_CR41","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","volume":"93","author":"BH Lee","year":"2019","unstructured":"Lee BH, Collins E, Lewis L, Guntrum D, Eichinger K, Voter K, et al. Combination therapy with nusinersen and avxs-101 in SMA type 1. Neurology. 2019;93(14):640\u20131.","journal-title":"Neurology"},{"issue":"4","key":"1320_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.27375","volume":"64","author":"KF Oechsel","year":"2021","unstructured":"Oechsel KF, Cartwright MS. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1. Muscle Nerve. 2021;64(4):487\u201390.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1320_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/15563650.2013.811588","volume":"51","author":"D Seger","year":"2013","unstructured":"Seger D, Barker K, Mcnaughton C. Misuse of the naranjo adverse drug reaction probability scale in toxicology. Clin Toxicol (Phila). 2013;51(6):461\u20136.","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01320-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:40:58Z","timestamp":1701920458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01320-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01320-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"25 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflicts of interest to disclose. There is no financial\/nonfinancial need to disclosures of all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The present pharmacovigilance study was conducted using a public database of spontaneous reports. Given the use of deidentified data, ethical approval was not considered necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The data are openly available in the FDA Adverse Event Reporting System Public Dashboard at: .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"FDA Adverse Event Reporting System is a spontaneous reporting system, the publicly available data are anonymized, and therefore, obtaining consent to participate is not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The custom code used in this study have been made available upon request. Please contact Dr. Wei Zhuang (zhuangw8@mail.sysu.edu.cn) for access to the code.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"WZ performed the main data analysis and statistics work, and wrote this manuscript. ML participated a part of data mining, gave the constructive suggestion and revised this manuscript. YW, ZC, MW, XW and SG participated the data cleaning and analysis. WL designed this study, critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}